Mutations in key genes of the alternative NF-kB pathway, such as BIRC3, confer resistance to BTK inhibitors in mantle cell lymphoma (MCL) [31,32], that can be overcome with the addition of NIK inhibitors [33]. Here, NFKB1 is linked to mantle cell lymphoma.